PURPOSE: To evaluate the association between use of antiplatelet or anticoagulant drugs and @entity5861 in @entity1 with neovascular @entity1020 ( @entity1020 ) in the Comparison of @entity1020 Treatments Trials (CATT). DESIGN: Cohort study within CATT. @entity1 : @entity1 in CATT with untreated active neovascular @entity1020 (n = 1185). METHODS: @entity1 were interviewed for use of antiplatelet or anticoagulant drugs. Trained readers evaluated photographs for the presence and size of @entity5861 at baseline and years 1 and 2. Associations between use of antiplatelet or anticoagulant drugs and @entity548 were evaluated among all @entity1 and by baseline @entity101 status using multivariate logistic regression models. MAIN OUTCOME MEASURES: Odds ratio for association with antiplatelet or anticoagulant use. RESULTS: Among 1165 @entity1 with gradable photographs, 724 (62.1%) had @entity5861 at baseline; 84.4% of @entity548 were 1 disc area (DA) or less, 8.1% were 1 to 2 DA, and 7.5% were more than 2 DA. At baseline, 608 @entity1 (52.2%) used antiplatelet or anticoagulant drugs, including 514 @entity1 (44.1%) using antiplatelets only, 77 (6.6%) using anticoagulants only, and 17 (1.5%) using both. @entity548 was present in 64.5% of antiplatelet or anticoagulant users and in 59.6% of nonusers (P  = 0.09; adjusted odds ratio [OR], 1.18; 95% confidence interval, 0.91-1.51; P  = 0.21). Neither presence nor size of baseline @entity548 was associated with the type, dose, or duration of antiplatelet or anticoagulant use. Forty-four of 1078 @entity1 (4.08%) had @entity5861 detected on 1- or 2-year photographs; these @entity548 were not associated with antiplatelet or anticoagulant use at baseline (P  = 0.28) or during follow-up (P  = 0.64). Among @entity1 with @entity101 (n  = 807), antiplatelet or anticoagulant use was associated with a higher rate of @entity548 at baseline (66.8% vs. 56.4%; adjusted OR, 1.48; P  = 0.01), but not size of @entity5861 (P  = 0.41). CONCLUSIONS: Most @entity5861 in eyes enrolled in CATT were less than 1 DA. Among all CATT participants, antiplatelet or anticoagulant use was not associated significantly with @entity548 , but it was associated significantly with @entity548 in @entity1 with @entity101 .

Association between Antiplatelet or Anticoagulant Drugs and XXXX in the Comparison of  Age-Related Macular Degeneration Treatments Trials.

@entity1 :: ('9606', 'Species') :: ['participants', 'Participants', 'PARTICIPANTS'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage', 'Hemorrhage', 'hemorrhages'] @entity5861 :: ('MESH:D012166', 'Disease') :: ['retinal or subretinal hemorrhages', 'retinal or subretinal hemorrhage'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['AMD', 'age-related macular degeneration']
@entity5861 :: (MESH:D012166,Disease) :: ['Retinal or Subretinal Hemorrhage']
